$GDLG
Glidelogic Corp.

2023 Q2 Form 10-Q Financial Statement

#000182912623004208 Filed on June 16, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2022 Q2 2021 Q4
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $105.00 $1.230K
YoY Change -91.46%
% of Gross Profit
Operating Expenses $8.750K $3.630K $3.810K
YoY Change 141.05%
Operating Profit -$8.750K -$3.630K $3.810K
YoY Change 141.05%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax $762.00
% Of Pretax Income
Net Earnings -$8.750K -$3.630K -$3.048K
YoY Change 141.05%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 2.664M shares 2.008M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2022 Q2 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.900K
YoY Change
Cash & Equivalents $5.902K $26.81K $20.73K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.902K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $3.648K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.648K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $5.902K
Total Long-Term Assets $3.648K
Total Assets $9.550K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $6.010K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.010K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.010K
Total Long-Term Liabilities $0.00
Total Liabilities $6.010K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$25.01K
YoY Change
Common Stock $2.664K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.540K $23.27K $14.97K
YoY Change
Total Liabilities & Shareholders Equity $9.550K
YoY Change

Cashflow Statement

Concept 2023 Q2 2022 Q2 2021 Q4
OPERATING ACTIVITIES
Net Income -$8.750K -$3.630K -$3.048K
YoY Change 141.05%
Depreciation, Depletion And Amortization $105.00 $1.230K
YoY Change -91.46%
Cash From Operating Activities -$8.645K -$7.900K
YoY Change 9.43%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $0.00
YoY Change
NET CHANGE
Cash From Operating Activities -$8.645K -$7.900K
Cash From Investing Activities $0.00
Cash From Financing Activities $0.00
Net Change In Cash -$8.645K $0.00
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$8.645K -$7.900K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 dei Entity Central Index Key
EntityCentralIndexKey
0001848672
CY2023Q2 dei Amendment Flag
AmendmentFlag
false
CY2023Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--01-31
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
CY2022Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
CY2023Q2 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
usd
CY2022Q2 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
usd
CY2023Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
CY2023Q2 us-gaap Interest Paid
InterestPaid
usd
CY2022Q2 us-gaap Interest Paid
InterestPaid
usd
CY2023Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2022Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2023Q2 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
usd
CY2023Q2 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q2 dei Document Type
DocumentType
10-Q
CY2023Q2 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q2 dei Document Period End Date
DocumentPeriodEndDate
2023-04-30
CY2023Q2 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q2 dei Entity File Number
EntityFileNumber
333-254750
CY2023Q2 dei Entity Registrant Name
EntityRegistrantName
GLIDELOGIC CORP.
CY2023Q2 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q2 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1575837
CY2023Q2 dei Entity Address Address Line1
EntityAddressAddressLine1
11264 Playa Court
CY2023Q2 dei Entity Address City Or Town
EntityAddressCityOrTown
Culver City
CY2023Q2 dei Entity Address Country
EntityAddressCountry
CA
CY2023Q2 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90230
CY2023Q2 dei City Area Code
CityAreaCode
310
CY2023Q2 dei Local Phone Number
LocalPhoneNumber
397-2300
CY2023Q2 dei Contact Personnel Email Address
ContactPersonnelEmailAddress
[email protected]
CY2023Q2 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q2 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2023Q2 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q2 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q2 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q2 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q2 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2663750 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5902 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14547 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
5902 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
14547 usd
CY2023Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
3648 usd
CY2023Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
3753 usd
CY2023Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
3648 usd
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
3753 usd
CY2023Q2 us-gaap Assets
Assets
9550 usd
CY2023Q1 us-gaap Assets
Assets
18300 usd
CY2023Q2 us-gaap Loans Payable Current
LoansPayableCurrent
6010 usd
CY2023Q1 us-gaap Loans Payable Current
LoansPayableCurrent
6010 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6010 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6010 usd
CY2023Q2 us-gaap Liabilities
Liabilities
6010 usd
CY2023Q1 us-gaap Liabilities
Liabilities
6010 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2663750 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2663750 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2663750 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2663750 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
2664 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
2664 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25886 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25886 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25010 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16260 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3540 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
12290 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9550 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18300 usd
CY2023Q2 us-gaap Revenues
Revenues
-0 usd
CY2022Q2 us-gaap Revenues
Revenues
-0 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8750 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3630 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
8750 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3630 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8750 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3630 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8750 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3630 usd
CY2023Q2 gdlg Net Lossincome Per Share Basic And Diluted
NetLossincomePerShareBasicAndDiluted
-0.00
CY2022Q2 gdlg Net Lossincome Per Share Basic And Diluted
NetLossincomePerShareBasicAndDiluted
-0.00
CY2023Q2 gdlg Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
2663750 shares
CY2022Q2 gdlg Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
2663750 shares
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
26898 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3630 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23268 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
12290 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8750 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3540 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8750 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3630 usd
CY2023Q2 us-gaap Depreciation
Depreciation
105 usd
CY2022Q2 us-gaap Depreciation
Depreciation
1230 usd
CY2022Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5500 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8645 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7900 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-8645 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7900 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14547 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34713 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5902 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26813 usd
CY2021Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
156250 shares
CY2021Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6250 usd
CY2021Q4 us-gaap Share Price
SharePrice
0.04
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2663750 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2663750 shares
CY2023Q2 us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_zHFsSXt7YHc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_861_zrVdQMydSg7a">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to the limited level of operations, the Company has not had to make material assumptions or estimates other than the assumption that the Company is a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2663750 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2663750 shares
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8953 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8953 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5200 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease
105 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5305 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3648 usd
CY2023Q2 us-gaap Loans Payable
LoansPayable
6010 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
128750 shares
CY2021Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5150 usd
CY2021Q4 us-gaap Share Price
SharePrice
0.04
CY2021Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
378750 shares
CY2021Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15150 usd
CY2021Q4 us-gaap Share Price
SharePrice
0.04
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25010 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5252 usd
CY2023Q2 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1993 usd
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25010 usd
CY2023Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16260 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5252 usd
CY2023Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3415 usd
CY2023Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
5252 usd
CY2023Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3415 usd
CY2023Q2 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1993 usd
CY2022Q2 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-3259 usd
CY2023Q2 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1993 usd
CY2022Q2 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3259 usd

Files In Submission

Name View Source Status
0001829126-23-004208-index-headers.html Edgar Link pending
0001829126-23-004208-index.html Edgar Link pending
0001829126-23-004208.txt Edgar Link pending
0001829126-23-004208-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gdlg-20230430.xsd Edgar Link pending
glidelogiccorp_10q.htm Edgar Link pending
glidelogiccorp_ex31-1.htm Edgar Link pending
glidelogiccorp_ex31-2.htm Edgar Link pending
glidelogiccorp_ex32-1.htm Edgar Link pending
glidelogiccorp_ex32-2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
gdlg-20230430_def.xml Edgar Link unprocessable
gdlg-20230430_cal.xml Edgar Link unprocessable
glidelogiccorp_10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
gdlg-20230430_pre.xml Edgar Link unprocessable
gdlg-20230430_lab.xml Edgar Link unprocessable